[HTML][HTML] Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab

DF McDermott, CG Drake, M Sznol… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
DF McDermott, CG Drake, M Sznol, TK Choueiri, JD Powderly, DC Smith, JR Brahmer…
Journal of clinical oncology, 2015ncbi.nlm.nih.gov
Purpose Blockade of the programmed death-1 inhibitory cell-surface molecule on immune
cells using the fully human immunoglobulin G4 antibody nivolumab mediates tumor
regression in a portion of patients with advanced treatment-refractory solid tumors. We report
clinical activity, survival, and long-term safety in patients with advanced renal cell carcinoma
(RCC) treated with nivolumab in a phase I study with expansion cohorts.
Abstract
Purpose
Blockade of the programmed death-1 inhibitory cell-surface molecule on immune cells using the fully human immunoglobulin G4 antibody nivolumab mediates tumor regression in a portion of patients with advanced treatment-refractory solid tumors. We report clinical activity, survival, and long-term safety in patients with advanced renal cell carcinoma (RCC) treated with nivolumab in a phase I study with expansion cohorts.
ncbi.nlm.nih.gov